Trials / Completed
CompletedNCT05715333
Study of CM326 Injection in Healthy Subjects
A Randomized, Double-blind, Placebo-controlled Phase I Clinical Study to Evaluate the Safety, Tolerance, Pharmacokinetics and Immunogenicity of CM326 Injection in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 46 (actual)
- Sponsor
- Keymed Biosciences Co.Ltd · Industry
- Sex
- Male
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
This study is a single-center, randomized, double-blind, placebo-controlled, dose-increasing phase I clinical study.
Detailed description
The purpose of this study is to evaluate the safety, tolerance, pharmacokinetics and immunogenicity of single and multiple subcutaneous administration of CM326 at different doses in healthy male subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | CM326 | CM326 Injection |
| OTHER | Placebo | Subcutaneous injection |
Timeline
- Start date
- 2023-03-21
- Primary completion
- 2023-10-04
- Completion
- 2023-10-04
- First posted
- 2023-02-08
- Last updated
- 2024-11-08
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05715333. Inclusion in this directory is not an endorsement.